Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …

Over the last decade remarkable progress has been made in enhancing the efficacy of CAR
T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in …

Recent genome‐wide studies have revealed that aging or chronic inflammation can cause
clonal expansion of cells in normal tissues. Clonal hematopoiesis has been the most …

Ten-eleven translocation (TET) proteins are iron-dependent and α-ketoglutarate-dependent
dioxygenases that sequentially oxidize the methyl group of 5-methylcytosine (5mC) to 5 …

In recent years, the tumour microenvironment (TME) of solid tumours has attracted more and
more attention from researchers, especially those non-tumour components such as immune …

The functional decline in T cells during their chronic stimulation, commonly referred to as T
cell exhaustion, is a major limitation for current immunotherapy approaches. As modern …

The family of ten-eleven translocation dioxygenases (TETs) consists of TET1, TET2, and
TET3. Although all TETs are expressed in hematopoietic tissues, only TET2 is commonly …

Effective immunotherapy treats cancers by eradicating tumourigenic cells by activated
tumour antigen-specific and bystander CD8+ T-cells. However, T-cells can gradually lose …

Aberrant innate immune signaling in myelodysplastic syndrome (MDS) hematopoietic
stem/progenitor cells (HSPCs) has been implicated as a driver of the development of MDS …